Acute Leukemias - Republican Scientific Medical Library
Acute Leukemias - Republican Scientific Medical Library
Acute Leukemias - Republican Scientific Medical Library
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
212 Chapter 16 · Treatment of Lymphoblastic Lymphoma in Adults<br />
other studies with relapses up to 5 years [7]. Also pretreatment<br />
with CYCLO pulses may play a role in T-<br />
LBL. In T-ALL the introduction of pretreatment with<br />
fractionated CYCLO in one study lead to a reduction<br />
of failure rate from 5/39 without CYCLO pretreatment<br />
to 0/8 with pretreatment [58]. The efficacy of fractionated<br />
CYCLO is also underlined by the successful hyper-CVAD<br />
regimen [18].<br />
New cytostatic drugs such as 2-CDA, forodesine Hydrochloride,<br />
and nelarabine with specific activity on Tcells<br />
or immunotherapy with T-cell specific antibodies<br />
such as anti-CD3 and anti-CD52 (Campath) deserve<br />
evaluation in relapsed and refractory patients. For nelarabine<br />
it was shown recently that it is equally effective<br />
in relapsed T-ALL and T-LBL with response rates of 42<br />
and 38%, respectively [59]. This drug is of interest not<br />
only for salvage therapy but also for integration in<br />
front-line therapy of T-LBL<br />
SCT may have a role in the treatment of high-risk<br />
patients with T-LBL although it is still not clear how<br />
high-risk patients have to be defined in the context of<br />
contemporary intensive ALL-type regimens. Particularly<br />
before auto SCT, intensive chemotherapy aiming to a<br />
high CR rate and effective tumor reduction seems to be<br />
necessary. New prognostic factors are required to define<br />
indications for SCT in first remission. The better characterization<br />
of biologic markers, e.g., immunophenotype<br />
of T-LBL, may contribute to this aim. Methods<br />
for MRD evaluation from bone marrow or even peripheral<br />
blood have to be established. Microarray analyses<br />
may contribute to characterization of disease biology<br />
and identification of new prognostic markers. It was already<br />
demonstrated that the majority of T-LBL patients<br />
show individual T-cell receptor rearrangements similarly<br />
to T-ALL. Thus, in the future, indications for SCT may<br />
be based at least partly on the evaluation of MRD.<br />
References<br />
1. The Non-Hodgkin’s Lymphoma Classification Project (1997) A clinical<br />
evaluation of the International Lymphoma Study Group classification<br />
of non-Hodgkin’s lymphoma. Blood 89:3909–3918<br />
2. Groves FD, Linet MS, Travis LB, Devesa SS (2000) Cancer surveillance<br />
series: Non-Hodgkin’s lymphoma incidence by histologic<br />
subtype in the United States from 1978 through 1995. J Natl Cancer<br />
Inst 92:1240–1251<br />
3. Harris NL, Jaffe ES, Diebold J, et al. (2000) The World Health Organization<br />
classification of neoplastic diseases of the haematopoietic<br />
and lymphoid tissues: Report of the Clinical Advisory Commit-<br />
tee Meeting, Airlie House, Virginia, November 1997. Histopathology<br />
36:69–86<br />
4. Raetz EA, Perkins SL, Bhojwani D, et al. (2006) Gene expression<br />
profiling reveals intrinsic differences between T-cell acute lymphoblastic<br />
leukemia and T-cell lymphoblastic lymphoma. Pediatr<br />
Blood Cancer 47:130–140<br />
5. Foon KA, Herzog P, Billing RJ, Terasaki PI, Feig SA (1981) Immunologic<br />
classification of childhood acute lymphocytic leukemia. Cancer<br />
47:280–284<br />
6. Jaffe ES, Berard CW (1978) Lymphoblastic lymphoma, a term rekindled<br />
with new precision. Ann Intern Med 89:415–417<br />
7. Reiter A, Schrappe M, Ludwig WD, et al. (2000) Intensive ALL-type<br />
therapy without local radiotherapy provides a 90% event-free survival<br />
for children with T-cell lymphoblastic lymphoma: A BFM<br />
group report. Blood 95:416–421<br />
8. Gökbuget N, Hoelzer D (2006) Treatment of adult acute lymphoblastic<br />
leukemia. Hematology Am Soc Hematol Educ Program, pp<br />
133–141<br />
9. Engelhard M, Brittinger G, Gerhartz HH, Kuse R, Steinke B (1996)<br />
Lymphoblastic lymphoma: Results of a prospective treatment trial<br />
(BMFT study). Br J Haematol 93:1391a<br />
10. Soslow RA, Baergen RN, Warnke RA (1999) B-lineage lymphoblastic<br />
lymphoma is a clinicopathologic entity distinct from other histologically<br />
similar aggressive lymphomas with blastic morphology.<br />
Cancer 85:2648–2654<br />
11. Hoelzer D, Gökbuget N, Digel W, et al. (2002) Outcome of adult<br />
patients with T-lymphoblastic lymphoma treated according to<br />
protocols for acute lymphoblastic leukemia. Blood 99:4379–<br />
4385<br />
12. Bernasconi C, Brusamolino E, Lazzarino M, et al. (1990) Lymphoblastic<br />
lymphoma in adult patients: Clinicopathological features<br />
and response to intensive multiagent chemotherapy analogous<br />
to that used in acute lymphoblastic leukemia. Ann Oncol<br />
1:141–146<br />
13. Santini G, Congiu AM, Coser P, et al. (1991) Autologous bone marrow<br />
transplantation for adult advanced stage lymphoblastic lymphoma<br />
in first CR. A study of the NHLCSG. Leukemia 5(Suppl)1:<br />
42–45<br />
14. Morel P, Lepage E, Brice P, et al. (1992) Prognosis and treatment of<br />
lymphoblastic lymphoma in adults: A report on 80 patients. J Clin<br />
Oncol 10:1078–1085<br />
15. Zinzani PL, Bendandi M, Visani G, et al. (1996) Adult lymphoblastic<br />
lymphoma: Clinical features and prognostic factors in 53 patients.<br />
Leuk Lymphoma 23:577–582<br />
16. Bouabdallah R, Xerri L, Bardou VJ, et al. (1998) Role of induction<br />
chemotherapy and bone marrow transplantation in adult lymphoblastic<br />
lymphoma: A report on 62 patients from a single center.<br />
Ann Oncol 9:619–625<br />
17. Sweetenham JW, Pearce R, Taghipour G, et al. (1997) Adult Burkitt’s<br />
and Burkitt-like non-Hodgkin’s lymphoma7Outcome for patients<br />
treated with high-dose therapy and autologous stem-cell<br />
transplantation in first remission or at relapse: Results from the<br />
European Group for Blood and Marrow Transplantation. J Clin Oncol<br />
14:2465–2472<br />
18. Thomas DA, O’Brien S, Cortes J, et al. (2004) Outcome with the<br />
hyper-CVAD regimens in lymphoblastic lymphoma. Blood<br />
104:1624–1630